BEIJING - Despite instability in the Middle East and North Africa, the leadership of Mindray Medical International is pressing ahead with plans to expand sales in international markets and is projecting a rise in net earnings of more than 10% in 2011
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
One Phase III trial hits but a second study misses by a mile.
